300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis

ABSTRACT

Introduction: The once-daily 300 index of reactivity (IR) house dust mite (HDM) tablet (Actair®; Stallergenes Greer, Antony, France/Shionogi & Co. Ltd., Osaka, Japan) is the first sublingual immunotherapy (SLIT) tablet to be approved for the treatment of HDM-induced allergic rhinitis.

Areas covered: This drug profile reviews the current body of evidence on the efficacy, safety and tolerability of the 300 IR HDM tablet, its pharmacodynamics, and its role in clinical practice.

Expert commentary: Data from its clinical development program demonstrate favorable efficacy and safety in adults and adolescents with HDM-induced allergic rhinitis, irrespective of mono- or polysensitization status, or the presence of comorbid mild asthma. The 300 IR HDM tablet is effective from as early as 2 months after treatment initiation, providing allergic symptom control and a reduction in the need for symptomatic medication, while improving health-related quality of life. Clinical efficacy is maintained for 1 year after treatment is stopped.

KEYWORDS:

• Allergy immunotherapy
• allergic rhinitis
• clinical trial
• efficacy
• house dust mite allergy
• safety
• sublingual immunotherapy

Declaration of interest

P Demoly has served as a consultant and speaker for ALK-Abelló, AstraZeneca, Chiesi, Stallergenes Greer and Thermo Fisher Scientific; and was a speaker for Allergopharma, AllergyTherapeutics, GlaxoSmithKline, Menarini and Merck in 2010–16. Y Okamoto has received consulting fees from Shionogi. WH Yang has been on the advisory board for BioCryst, Boehringer-Ingelheim, CSL Behring, Novartis, Shire and Teva and has given lectures on behalf of Astra Zeneca, CSL Behring, Novartis and Shire; has received research grants from Aimmune, ALK-Abellló, AstraZeneca, DBV Technologies, Merck, Novartis, Roche, Sanofi and Stallergenes Greer. P Devillier has received consulting fees from Stallergenes Greer and has received honoraria for board membership, consultancy, lectures, and/or manuscript preparation from ALK-Abelló, Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi, CLL Pharma, GlaxoSmithKline, Meda Pharma, Mundipharma, Novartis, Sandoz, Stallergenes Greer and Teva. K-C Bergmann has received honoraria for lectures from ALK-Abelló Arzneimittel GmbH, Bencard Allergie GmbH, Chiesi GmbH, and Novartis Pharma Arzneimittel GmbH; travel support from Mundipharma GmbH; and reimbursements for travel and data monitoring boards from Stallergenes Greer. Medical writing assistance in the preparation of this manuscript was provided by James Reed of Newmed Publishing Services, and funded by Stallergenes Greer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was funded by Stallergenes Greer.